Overview
- The University of Sheffield’s SITraN, working with US biotech Aclipse Therapeutics, reported preclinical results for M102 in Molecular Neurodegeneration.
- Mouse studies found slower disease progression with preserved movement, gait, nerve function and muscle strength compared with controls.
- The compound protected lab-grown motor neurones from damage caused by cells derived from people with motor neurone disease.
- Investigators led by Professor Dame Pamela Shaw say they are prepared to advance toward first-in-human trials, though no human testing has begun.
- Motor neurone disease remains a progressive, currently incurable condition affecting about 5,000 people in the UK, with many patients dying within two to five years of symptom onset.